CLAIMS

1. A compound having the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X, Z, and Z'** are independently CH or N; **m**=0-3; **n**= 0-4; R_1, R_2 are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and R_4, R_5 are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring, except that R_1 is H, R_2 is H, Cl or CF_3, R_3, R_4 and R_5 = H, Y = O and Q = CH when m=0 and n=1; and also except that R_1 is H, R_2 is OCH_3, R_3, R_4 and R_5 = H, Y=O, Q=CH when m=0 and n=2.

2. The compound of claim 1 having the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and ~~m'~~ = 1-4, except that R_1 is H, R_2 is H, Cl or CF_3 and R_3 is H when ~~m'~~ = 1 and n = 1; and also except that R_1 is H, R_2 is OCH_3 and R_3 is H when ~~m'~~ = 1 and n = 2.

3. The compound of claim 1 which is 1-[4-(4-fluorophenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

4. The compound of claim 1 which is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

5. The compound of claim 1 which is 1-[4-(2-pyridyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

6. The compound of claim 1 which is 1-[4-(~~pyrimidyl~~ (2-pyrimidyl))piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

7. The compound of claim 1 which is 1-[4-(3,4-dimethylphenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

8. The compound of claim 1 which is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-2-(2,5-dioxopyrrolidin-1-yl)ethane or its hydrochloride salt.

9. The compound of claim 1 which is 1-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

10. The compound of claim 1 which is 1-[4-(4-methoxyphenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

11. The compound of claim 1 which is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

12. The compound of claim 1 which is 1-[4-(4-fluorophenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

13. The compound of claim 1 which is 1-[4-(4-chlorophenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

14. The compound of claim 1 which is 1-[4-(3-trifluoromethylphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

15. The compound of claim 1 which is 1-[4-(2-fluorophenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

16. The compound of claim 1 which is 1-[4-(2-methylphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

17. The compound of claim 1 which is 1-[4-(2-pyridyl)piperazin-1-yl)-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

18. The compound of claim 1 which is 1-[4-(3-chlorophenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

19. The compound of claim 1 which is 1-[4-(3,4-dimethylphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

20. The compound of claim 1 which is 1-[4-(2-pyrimidyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

21. The compound of claim 1 which is 1-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

22. The compound of claim 1 which is 1-[4-(4-methoxyphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

23. The compound of claim 1 which is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-4-(2,6-dioxopiperidin-1-yl)butane or its hydrochloride salt.

24. The compound of claim 1 which is 1-[4-(2-Methoxyphenyl)piperazin-1-yl]-3-[2,5-dioxo-3-phenyl-pyrolidin-1-yl]propane or its hydrochloride salt.

25. The compound of claim 1 which is 1-[4-(Phenyl)piperidin-1-yl]-3-[2,5-dioxopyrolidin-1-yl]propane or its hydrochloride salt.

26. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

27. A method of selectively antagonizing α_1-adrenergic receptors in a mammal comprising administering to said mammal a compound having the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, amides, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X , Z, and Z'** are independently CH or N; **m**=0-3; **n**= 0-4; $\mathbf{R_1}$, $\mathbf{R_2}$ are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and R_4, R_5 are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring.

28. The method of claim 27 wherein said compound has the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and m' = 1-4.

29. The method of claim 28 wherein said compound is 1-[4-(2-methoxy-phenyl)piperazin-1yl]-3-(2,5-dioxopyrrolidin-1-yl) propane or its hydrochloride salt.

30. The method of claim 28 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-4-(2,5-dioxopyrrolidin-1-yl)butane or its hydrochloride salt.

31. The method of claim 28 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

32. A method for treating benign prostatic hypertrophy in a mammal comprising administering to said mammal a compound of the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, amides, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X Z, and Z'** are independently CH or N; **m**=0-3; **n**= 0-4; R_1, R_2 are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and R_4, R_5 are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring.

33. The method of claim 32 wherein said compound has the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and m' = 1-4.

34. The method of claim 33 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

35. The method of claim 33 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-4-(2,5-dioxopyrrolidin-1-yl)butane or its hydrochloride salt.

36. The method of claim 33 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

37. A method for treating vascular disease, congestive heart failure, or hypertension in a mammal comprising administering to said mammal a compound of the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, amides, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X, Z, and Z'** are independently CH or N; **m**=0-3; **n**= 0-4; R_1, R_2 are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and R_4, R_5 are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring.

38. The method of claim 37 wherein said compound has the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and m' = 1-4.

39. The method of claim 38 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,5-dioxopyrrolidin-1-yl)propane or its hydrochloride salt.

40. The method of claim 33 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-4-(2,5-dioxopyrrolidin-1-yl)butane or its hydrochloride salt.

41. The method of claim 33 wherein said compound is 1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(2,6-dioxopiperidin-1-yl)propane or its hydrochloride salt.

42. A method for making a compound having the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, amides, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X, Z and Z'** are independently CH or N; **m**=0-3; **n**= 0-4; $\mathbf{R_1}$, $\mathbf{R_2}$ are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and $\mathbf{R_4}$, $\mathbf{R_5}$ are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring,

which comprises reacting a compound having the structure of Formula III'



(III')

with a compound having the structure of Formula IV



(IV)

thereby to produce the compound of Formula I.

43. The method of claim 42 for producing a compound having the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and m' = 1-4,

which comprises reacting a compound having the structure of Formula III



(III)

with said compound of Formula IV

44. A method for making a compound having the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, amides, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X, Z** and **Z'** are independently CH or N; **m**=0-3; **n**= 0-4; $\mathbf{R_1}$, $\mathbf{R_2}$ are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and $\mathbf{R_4}$, $\mathbf{R_5}$ are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring,

which comprises reacting a compound having the structure of Formula VI'



(VI')

with a compound having the structure of Formula V



(V)

thereby to produce the compound of Formula I.

45. The method of claim 44 for producing a compound having the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and m' = 1-4,

which comprises reacting a compound having the structure of Formula VI



(VI)

with said compound of Formula V.

46. A method for making a compound having the structure of Formula I



(I)

its pharmaceutically acceptable salts, esters, amides, enantiomers, diastereomers, N-oxides, amides, prodrugs, or metabolites, wherein **Y** is O or S; **Q, X, Z** and **Z'** are independently CH or N; **m**=0-3; **n**= 0-4; R_1, R_2 are independently selected from: H, F, Cl, Br, OCH_3, OC_2H_5, OCH_2CF_3, SCF_3, CH_3, C_2H_5, CF_3, isopropyloxy, and cyclopropyl; R_3 is H, R_6, OH or OR_6; R_6 is a substituted or unsubstituted alkyl chain containing 1-6 carbon atoms; and R_4, R_5 are H, C_{1-3} alkyl, substituted or unsubstituted phenyl, or a 5-membered spiro ring,

which comprises reacting a compound having the structure of Formula VII'



(VII')

with a compound having the structure of Formula VIII



(VIII)

thereby to produce the compound of Formula I.

47. The method of claim 46 for producing a compound having the structure of Formula II



(II)

wherein n, X, Z, Z', R_1, R_2 and R_3 are as defined for Formula I and m' = 1-4,

which comprises reacting a compound having the structure of Formula VII.



(VII)

with said compound of Formula VIII.